BioDuro is Redefining CRDMO Partnerships With End-to-End Innovation
How BioDuro is expanding its global CRDMO footprint by improving integrated capabilities and delivering high-quality, end-to-end solutions for drug development and manufacturing
Armin Spura, PhD, CEO of BioDuro, talks about the company’s evolution into a fully integrated contract, research, and development manufacturing organization (CRDMO), offering seamless services across discovery to development and commercialization. Spura discusses recent expansions in commercial-scale API production, peptide scale-up, and high-potency capabilities at the company’s Bengbu, China location.
Watch this video and learn more about:
- What differentiates BioDuro as a high-touch, high-quality CRDMO and how its integrated model streamlines drug development.
- The company’s recent facility expansions in the U.S. and China in drug substance synthesis, peptide production, and more.
- How BioDuro navigates geopolitical and regulatory landscapes while scaling global operations and client-specific solutions.
Shilpa Medicare Launches ‘Hybrid CDMO’ at DCAT Week 2025
March 17th 2025This model is being positioned by Shilpa as a dual approach that offers comprehensive discovery, clinical, and commercial outsourcing services in addition to commercially ready, “off-the-shelf” novel formulations for b2b licensing.
